This week an FDA panel backed Valeant's skin drug brodalumab and then the regulator gave the thumbs up for an oral version of its constipation drug…

Initially it looked like a U.S. biotech to be the first; then a team funded by the billionaire co-founder of Napster; now, it looks like it will be Chinese…

InflaRx has raised $34 million in a Series C to at least get it through Phase II testing for its lead candidate, as well as to expand its preclinical pipeline.

Fresh off a positive FDA panel earlier this month for what could be its first approved biosimilar for Humira, Amgen--and partner Allergan--have reported…

Brexit rejig leaves the U.K. without a life science minister, Shire takes a stake in Chronos, Poxel postpones its IPO and more.

Galderma Pharma has picked up the rights to a midphase atopic dermatitis and pruritus drug from Roche’s Chugai Pharmaceutical.

Biogen’s long-standing CEO Dr. George Scangos is to step down from the company in “the coming months” as the Big Biotech looks for a successor.

After a year of takeover rumors that seemed to fizzle out into nothing, Relypsa has finally found its match in the biotech’s drug marketing partner and Swiss…